EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Advanced glycation end products are biomolecular biomarkers for proliferative diabetic retinopathy

Nibha Mishra, Sandeep Saxena, Rajendra K Shukla, Anshul Tiwari

Indian Journal of Ophthalmology · 2025-06 · 73 (6) · 906-911

DOI: 10.4103/ijo.ijo_2115_24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Ophthalmology, online erschienen am 17.04.2025. Verfasst von Nibha Mishra und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, King George's Medical University, Lucknow, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Glycation End Products, Advanced. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The present study examines the role of advanced glycation end products (AGEs) as biomolecular biomarkers for proliferative diabetic retinopathy (PDR). A cross-sectional study with a total of 80 consecutive cases of type 2 diabetes mellitus (DM) was divided into no retinopathy (NoDR) ( n = 20), non-proliferative diabetic retinopathy (NPDR) ( n = 20), PDR ( n = 20), and controls ( n = 20). AGEs were assessed by assay of N-carboxymethyl-lysine (Nε-CML). Nε- CML was evaluated using receiver operating characteristic curve (ROC) curve analysis, and the area under curve (AUC) was determined. The mean levels of Nε-CML were 31.3 ± 21.2 ng/mL, 73.9 ± 35.0 ng/mL, 91.2 ± 66.7 ng/mL, and 132.0 ± 84.0 ng/mL in control, NoDR, NPDR, and PDR, respectively. On analysis of variance (ANOVA), the Ne-CML level was significantly different between the study groups (control, NoDR, NPDR, and PDR) ( P < 0.001). Best-corrected visual acuity decreased with disease progression and increased levels of Ne-CML ( P < 0.001). On AUC analysis, the following values were obtained NoDR = 0.67, NPDR = 0.69, and PDR = 0.84, showing that AGEs are the most sensitive biomarkers for PDR in DR. AGEs serve as biomolecular biomarkers for PDR and can indicate disease conversion from NPDR to PDR. They are new-age tools of translational medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic RetinopathyGlycation End Products, AdvancedHumansCross-Sectional StudiesBiomarkersMaleFemaleMiddle AgedROC CurveAdultDiabetes Mellitus, Type 2Visual AcuityFollow-Up StudiesLysineDisease ProgressionAged

Stichwörter der Autor:innen

Advanced glycation end productsNε – carboxymethyl lysinebiomarkerdiabetes mellitusdiabetic retinopathy

Substanzen

Glycation End Products, AdvancedBiomarkersN(6)-carboxymethyllysineLysine

Autor:innen und Institutionen

  • Department of Ophthalmology, King George's Medical University, Lucknow, Uttar Pradesh, India.
  • Developmental Toxicology Division, CSIR-Indian Institute of Toxicological Research, Lucknow, Uttar Pradesh, India.
  • Department of Biochemistry, State Medical College, Bahraich, Uttar Pradesh, India.
  • Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee, USA.

Zitieren

APA

Mishra, N., Saxena, S., Shukla, R. K., & Tiwari, A. (2025). Advanced glycation end products are biomolecular biomarkers for proliferative diabetic retinopathy. Indian Journal of Ophthalmology, 73(6), 906-911. https://doi.org/10.4103/ijo.ijo_2115_24

Vancouver

Mishra N, Saxena S, Shukla RK, Tiwari A. Advanced glycation end products are biomolecular biomarkers for proliferative diabetic retinopathy. Indian Journal of Ophthalmology. 2025;73(6):906-911. doi:10.4103/ijo.ijo_2115_24

BibTeX
@article{Mishra2025,
  author = {Mishra, Nibha and Saxena, Sandeep and Shukla, Rajendra K and Tiwari, Anshul},
  title = {Advanced glycation end products are biomolecular biomarkers for proliferative diabetic retinopathy},
  journal = {Indian Journal of Ophthalmology},
  year = {2025},
  volume = {73},
  number = {6},
  pages = {906--911},
  doi = {10.4103/ijo.ijo_2115_24}
}
Kostenlos starten →